Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Parkinson's Disease
100%
Response Inhibition
100%
Atomoxetine
100%
Locus Coeruleus
100%
Noradrenergic
75%
Stop Signal Reaction Time
37%
Patients with Parkinson's Disease
37%
Placebo
25%
Noradrenaline
25%
Neuromelanin
25%
Therapeutic Potential
12%
Control Subjects
12%
Patient Selection
12%
Stop-signal Task
12%
Cognitive Decline
12%
Clinical Trials
12%
Treatment Response
12%
Cognitive Deficits
12%
Therapeutic Strategies
12%
Placebo-controlled
12%
Inpatient Treatment
12%
Randomized Crossover Design
12%
Psychopharmacological
12%
Ultra-high Field
12%
Magnetization Transfer
12%
Neurotransmitter Systems
12%
Neuromodulatory Systems
12%
Race Model
12%
Ex-Gaussian
12%
Dopaminergic Therapy
12%
Inhibition Deficit
12%
Hierarchical Bayesian Estimation
12%
Drug Manipulation
12%
Neuroscience
Parkinson's Disease
100%
Locus Coeruleus
100%
Atomoxetine
100%
Placebo
37%
Neuromelanin
37%
Cognitive Disorder
12%
Dopaminergic
12%
Reuptake Inhibitor
12%
Neurotransmitter
12%
Magnetization Transfer
12%
Norepinephrine
12%
Noradrenalin Level
12%
Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
100%
Atomoxetine
100%
Placebo
42%
Neuromelanin
42%
Noradrenalin
28%
Clinical Trial
14%
Cognitive Defect
14%
Dopamine Receptor Stimulating Agent
14%
Reuptake Inhibitor
14%
Neurotransmitter
14%